AI-Enabled Software As A Medical Device Market Report Scope & Overview:

The AI-Enabled Software As A Medical Device Market was valued at USD 9.18 Billion in 2025 and is expected to reach USD 62.53 Billion by 2035, growing at a CAGR of 21.15% from 2026-2035.

The AI-Enabled Software As A Medical Device Market covers regulated software that applies machine learning to identify, diagnose, monitor or direct treatment without being embedded in a hardware device. Growth is driven by clinician shortages, rising imaging volumes and a steady flow of regulatory clearances. Therapeutic software is growing in popularity, but diagnostic software accounts for the largest share of the market. Radiology and imaging are the leading clinical specialties and pathology is fast growing. Hospitals are the largest end users, although home healthcare is growing more quickly. North America is the most mature region in terms of regulatory environment, while Asia Pacific is the fastest growing region. These factors support robust growth up to 2035.

In September 2026, Tempus AI received FDA 510(k) clearance for Tempus ECG-MR, which analyzes standard 12-lead resting electrocardiograms to flag undiagnosed moderate or severe mitral regurgitation. As the company's fourth FDA-cleared ECG-AI product, it shows how cleared software is extending beyond imaging into routine cardiac testing.

U.S. AI-Enabled Software As A Medical Device Market Outlook

The U.S. AI-Enabled Software As A Medical Device Market was valued at USD 3.42 Billion in 2025 and is expected to reach USD 24.09 Billion by 2035, growing at a CAGR of 21.57% from 2026-2035.

The U.S. AI-Enabled Software As A Medical Device Market is the largest national market in the world. The Food and Drug Administration has authorized more AI-enabled devices than any other regulator, and its clear pathways for clearance and change control encourage investment. Large health systems, imaging networks and academic centers deploy triage and detection software at scale. Insurers are beginning to cover selected algorithms, which supports adoption. Concerns about validation, bias and cybersecurity remain. Even so, the market is projected to expand at a strong pace through 2035 as more clinical indications gain clearance. Growing interest from payers and employers in earlier detection adds further momentum.

⮞In January 2026, Cleerly announced that Aetna would begin covering its Cleerly LABS AI-based coronary plaque analysis, joining UnitedHealthcare, Cigna and Humana. Wider commercial coverage strengthens the reimbursement case for U.S. buyers and supports adoption beyond early academic users.

By Software Type, Diagnostic Dominates the AI-Enabled Software As A Medical Device Market and Therapeutic Grows Fastest

Diagnostic software holds the largest share because detection, triage and measurement algorithms were the first to win regulatory clearance and show clear clinical value. These products flag suspected strokes, bleeds, nodules, fractures and cardiac abnormalities so that clinicians can act sooner, and they fit into existing imaging and cardiology workflows with little disruption. Hospitals can measure their effect through shorter turnaround times and fewer missed findings, which makes purchase decisions simpler. A large catalog of cleared indications from many vendors also gives buyers a wide choice. These strengths keep the segment well ahead of other software types in revenue.

Therapeutic software is growing at the faster pace as developers apply machine learning to prescription digital therapies, treatment planning and personalized dosing support. Programs for mental health, chronic disease self-management and rehabilitation adjust content to each patient using data collected between visits. Regulators have created clearer routes for such products, and payers are testing coverage models. Because these tools can be delivered through smartphones, they reach patients outside clinics at low cost. Although the base is smaller than diagnostics, strong evidence from trials and rising patient demand for home-based care support rapid expansion.

⮞In November 2025, RapidAI received FDA clearance for five imaging modules, Rapid DeltaFuse, Rapid LMVO, Rapid MLS, Rapid OH and Rapid Aortic, on its Rapid Enterprise Platform. Each module adds a detection or measurement task, reinforcing the commercial lead of diagnostic software.

By Clinical Specialty, Radiology and Imaging Dominates the AI-Enabled Software As A Medical Device Market and Pathology Grows Fastest

Radiology and imaging leads because digital images are abundant, standardized and well suited to machine learning. Algorithms review computed tomography, magnetic resonance, X-ray and mammography studies to prioritize urgent cases, measure structures and highlight suspicious areas. Picture archiving systems provide ready integration points, and vendor-neutral marketplaces let departments add new algorithms without separate installations. Vendors have built large evidence bases, and health systems often install several algorithms together on one platform. This maturity and the number of cleared products keep radiology far ahead of other specialties in market share.

Pathology is the fastest growing specialty as laboratories digitize glass slides and adopt algorithms for cancer detection, grading and biomarker scoring. Whole-slide scanners generate very large images that are difficult to review manually, so software that finds suspicious regions saves pathologist time and improves consistency. Regulators have authorized the first prostate and breast tools, which gives other developers a reference path. Growing cancer incidence and the shift toward biomarker-guided therapy add urgency. Although adoption began later than radiology, investment in digital laboratories and companion diagnostics is pushing growth ahead of the wider market.

⮞In March 2026, Harrison.ai received FDA 510(k) clearance for acute infarct triage on non-contrast CT brain scans, bringing its cleared indications to 13. Broader finding coverage on routine scans strengthens the lead of radiology and imaging over other specialties.

By End User, Hospitals Dominate the AI-Enabled Software As A Medical Device Market and Home Healthcare Settings Grow Fastest

Hospitals account for the largest share because they own the imaging systems, electronic records and specialist teams needed to deploy regulated software. Emergency departments, stroke centers, cancer programs and cardiology units use algorithms for triage and decision support around the clock. Central information technology and governance teams can evaluate vendors, verify performance and roll out tools over many sites. Enterprise contracts and large volumes of purchases give vendors stable income. Academic medical centers are also early adopters and evidence generators that pressure community hospitals to do the same. These factors keep hospitals well ahead of other care settings.

Home healthcare settings are expanding fastest as software moves toward continuous monitoring and patient self-management. Smartwatch electrocardiogram algorithms, smartphone retinal screening and remote patient monitoring platforms use machine learning to flag changes that require a clinician visit. Aging populations, preference for care at home and pressure to reduce hospital stays all support growth. Reimbursement for remote monitoring is slowly improving, and consumer devices already provide the sensors and connectivity needed. Although the installed base is still small, low delivery cost and rising patient acceptance are pushing this setting ahead of the wider market.

⮞In July 2026, Viz.ai reported that its platform is deployed in 2,000 U.S. hospitals, supported by 13 FDA clearances accumulated over ten years. Enterprise-wide deployment on this scale illustrates why hospitals remain the dominant end-user setting.

By Deployment Mode, Cloud-Based Dominates the AI-Enabled Software As A Medical Device Market and Hybrid Grows Fastest

Cloud-based deployment leads because it lets vendors update algorithms centrally, scale computing for large imaging files and connect many sites through one contract. Hospitals avoid buying and maintaining local servers, and they can add new algorithms from a marketplace without separate installations. Subscription pricing spreads cost over time and matches payment to usage. Security certifications and secure data exchange standards have eased early concerns about hosting patient data off site. Platform providers also use cloud tools to monitor algorithm performance across customers. These features make cloud delivery the default for new deployments and for multi-site health systems.

Hybrid deployment is growing fastest as providers combine local processing with cloud management. Time-critical tasks such as stroke triage run close to the scanner to avoid delay, while model updates, monitoring and analytics are handled in the cloud. This approach also helps organizations that must keep data within national borders or hospital networks. Edge computing hardware is becoming cheaper, and regulators expect manufacturers to monitor real-world performance, which favors connected designs. Large health systems with mixed legacy and modern infrastructure find hybrid models practical, and growing demand for low-latency decision support is lifting adoption faster than for other modes.

⮞In April 2026, Us2.ai entered a reseller relationship under which Canon Medical Systems USA offers its cloud-based echocardiography software alongside Aplio i-series ultrasound systems. Distribution through an imaging vendor's sales channel shows how cloud delivery lowers the barrier to adding algorithms.

Regional Analysis

North America AI-Enabled Software As A Medical Device Market Insights

With a share of 40.73% in 2025, North America led the market. The U.S. anchors regional demand through the largest number of regulatory clearances, a deep base of venture-funded developers and health systems that adopt algorithms early. Canada adds growing hospital use under provincial programs and a licensing route through Health Canada. Large integrated delivery networks, teleradiology groups and academic centers buy software across imaging, cardiology and oncology. Strong research funding supports steady uptake of cleared products across hospitals and clinics. Medicare's New Technology Add-on Payment program has also rewarded selected triage algorithms, giving hospitals a direct route to offset deployment costs.

Partnerships between algorithm vendors, imaging equipment makers and cloud providers make deployment easier, and several large health systems now run enterprise-wide AI programs rather than department-level pilots. Integrated delivery networks increasingly negotiate multi-year platform agreements that bundle triage, measurement and care coordination tools under one contract. Procurement teams still expect local validation before scaling. Even so, the region keeps its lead through its concentration of technology companies, patient data resources and well-funded health systems, which together create the largest pool of customers for cleared AI software. Rural hospitals are also joining regional networks that use cloud-delivered triage to speed transfers for stroke and cardiac patients.

⮞In April 2026, AliveCor partnered with WELL Health Technologies to provide cardiologist review within 24 hours of Kardia ECG recordings for Canadian users, supported by WELL's network of more than 250 clinics. The arrangement widens access to AI-enabled cardiac monitoring in Canada.

Europe AI-Enabled Software As A Medical Device Market Insights

Europe is the second-largest region, supported by strong clinical research, national health systems and a regulatory framework that certifies software under the Medical Device Regulation. Germany leads through hospital digitization programs and its large imaging market. The U.K., France, Spain and the Nordic countries add active public screening programs and home-grown developers in imaging, stroke and cardiology. Cross-border research collaborations also help developers share data and validate tools across populations. Large radiology groups and laboratory networks are adopting triage and autonomous reading tools for routine examinations such as chest X-rays. Several national screening programs are testing software as a second reader for mammography.

The interaction between the Medical Device Regulation and the Artificial Intelligence Act shapes development plans, because high-risk software must meet both sets of rules. Notified body capacity and documentation demands can lengthen time to market. Consolidation is under way as imaging software groups acquire specialist algorithm companies. Public procurement favors products with strong evidence, and data protection rules require careful design. Nevertheless, the region offers a large, well-organized customer base and a trusted regulatory brand that supports steady growth through 2035. Professional societies also publish guidance that helps hospitals select and monitor tools.

⮞In April 2026, Sectra of Sweden completed its acquisition of Oxipit of Lithuania, announced in March 2026, adding ChestLink, the first autonomous chest X-ray AI with CE Class IIb certification. Acquisitions of this kind are consolidating European imaging software.

Asia Pacific AI-Enabled Software As A Medical Device Market Insights

Asia Pacific is the fastest-growing region, projected to expand at a CAGR of 24.26% from 2026 to 2035. China leads regional demand through large hospital networks, government support for medical artificial intelligence and a growing list of registered products. Japan contributes mature imaging infrastructure and an aging population, while South Korea hosts leading imaging algorithm developers that sell abroad. India adds high screening volumes and a fast-growing group of start-ups that tackle chest, brain and cancer imaging in resource-limited settings. Large public hospital groups also run pilots that can scale quickly once results are proven.

Governments are adapting rules and regulations to review software as a device which makes the approval routes clearer. Large patient populations provide the data to train and refine models, and high-volume public screening programs give developers rapid feedback on real-world performance. Regional rollouts can be slowed down by fragmented regulations across countries, uneven digital infrastructure and local data rules. Even with these constraints, the scale of healthcare investment, rapid digitization of hospitals and strong local developer ecosystems provide the region the strongest growth momentum through 2035. Growing private insurance cover backs demand in big cities.

⮞In December 2025, Lunit of South Korea submitted a premarket notification to the U.S. Food and Drug Administration for Lunit INSIGHT Risk, a mammography-based breast cancer risk prediction model. Regional developers are increasingly seeking global clearances.

MEA & Latin America AI-Enabled Software As A Medical Device Market Insights

The Middle East and Africa is a smaller but fast-modernizing region. Gulf states are building national digital health programs, virtual hospitals and local regulatory capacity, and they are beginning to authorize software developed by regional start-ups. Saudi Arabia and the UAE lead spending, while Qatar invests in advanced hospital systems. In Africa, South Africa has the most developed healthcare technology base, and imaging software is being used to extend specialist reading to remote clinics. Limited reimbursement, small specialist workforces and uneven connectivity slow broader adoption.

Latin America adds demand through public and private hospital networks that use imaging software to extend scarce radiology expertise. Brazil leads regional purchasing, followed by Mexico, Argentina and Colombia. Regulators such as the national agencies in Brazil and Mexico are building recognition pathways for software devices, which supports market entry for global vendors. Currency swings, import costs and budget limits can delay projects. Nevertheless, growing teleradiology services, rising chronic disease burden and expanding private insurance support a steady increase in demand for regulated AI software through 2035.

⮞In September 2026, the Saudi Food and Drug Authority granted marketing authorization to two Saudi-developed artificial intelligence medical software products for dental X-ray and retinal image analysis. Local authorization routes are opening the Gulf market to regional developers.

Market Dynamics

Growth Drivers: Clinician shortages, rising imaging volumes and expanding regulatory clearances are accelerating adoption

The strongest driver is the gap between clinical workload and workforce supply. Imaging volumes, cancer screening programs and chronic disease monitoring all grow faster than the number of radiologists, pathologists and cardiologists. Software that triages urgent cases, automates measurements and drafts structured findings helps teams manage queues and reduce delays. Hospitals value tools that shorten time to treatment in conditions such as stroke and cardiac events, where minutes matter. As more departments report daily use of algorithms, peer experience lowers perceived risk for those that have not yet adopted them.

A second driver is the steady flow of regulatory clearances and clearer guidance. Each new authorization widens the set of indications that buyers can use, and frameworks for planned algorithm updates encourage continuous improvement. Vendors now publish larger external validation datasets, which shortens hospital due-diligence cycles. Growing clinical evidence from large trials strengthens the case for adoption, and Category I CPT coding for AI-based coronary plaque analysis from January 2026 gives one clinical use a permanent billing route. Advances in model design, computing power and access to imaging data further improve accuracy and extend software into new specialties.

⮞In August 2026, iRhythm Holdings received FDA clearance for its third-generation Zio ECG detection algorithm, which the company expects to cut clinical technician review time by about 50%. Productivity gains of this size show how software helps providers absorb rising diagnostic volumes.

Restraints: Validation gaps, bias concerns and cybersecurity risks slow clinical trust and adoption

Evidence and transparency gaps are a persistent restraint. Many algorithms are cleared with limited public detail on training data, patient mix or performance across subgroups, which makes it hard for hospitals to judge how a tool will perform in their own population. Performance can drift when scanners, protocols or patient groups change, so local validation and monitoring are needed. These checks require data science staff that many hospitals lack. Clinicians may also worry about over-reliance on automated outputs, and liability rules for software errors remain unsettled in many countries.

Regulatory and security issues add pressure. Developers must navigate different rules in each region, and overlapping requirements for medical device and artificial intelligence laws increase documentation work. Connected software expands the attack surface for hospital networks, so buyers ask for strong security and update practices. Integration with legacy records and imaging systems can be slow and expensive. Reimbursement is still limited for many tools, which makes return on investment hard to show. These factors moderate the pace of adoption, particularly among smaller hospitals and in lower-income markets.

Opportunities: Generative artificial intelligence, new clinical indications and home-based monitoring are opening new demand

Generative artificial intelligence presents a major opportunity. Vision-language models can draft preliminary findings from images for radiologist review, which targets the reporting step that consumes much of a reader's time. Regulators are engaging with these tools through breakthrough designations and advisory committees, signaling a path to market. Developers that combine detection, measurement and report drafting in one platform can raise the value of each examination. Health systems struggling with reading backlogs are likely to be early buyers, creating a large new revenue pool for software vendors.

New indications and care settings offer additional openings. Software for cardiology, ophthalmology, pathology, neurology and primary care is still at an early stage compared with radiology, and many conditions lack a cleared algorithm. Home monitoring on watches and phones can screen for heart rhythm, blood pressure and eye disease outside clinics. Emerging markets building national digital health systems offer further volume for locally authorized products. Vendors that demonstrate clinical outcomes, offer flexible pricing and support continuous monitoring can build long-term contracts across these segments.

⮞In March 2026, Philips received FDA 510(k) clearance for EchoNavigator R5.0 with DeviceGuide, AI-enabled software developed with Edwards Lifesciences to guide mitral transcatheter edge-to-edge repair. Procedure guidance is a new indication class that extends AI software into interventional cardiology.

AI-Enabled Software As A Medical Device Market Key Players

• Aidoc Medical Ltd.

• Viz.ai, Inc.

• Qure.ai Technologies Private Limited

• Lunit Inc.

• RapidAI

• Heartflow, Inc.

• Cleerly, Inc.

• Brainomix Limited

• Eyenuk, Inc.

• Digital Diagnostics Inc.

• Tempus AI, Inc.

• Ultromics Ltd.

• Us2.ai

• Harrison.ai

• RadNet, Inc.

• Sectra AB

• Eko Health, Inc.

• AliveCor, Inc.

• Koninklijke Philips N.V.

• iRhythm Holdings, Inc.

AI-Enabled Software As A Medical Device Market Report Scope: